Home > Activities > ESMO Symposium > Testicular 2008

ESMO Symposium on Testicular Cancer

Munich, Germany

15-16 May 2008

Hans-Joachim Schmoll, Germany
ESMO Symposium on Testicular Cancer Scientific Committee Chair

Testicular cancer is the most frequent tumor occurring in young men between the ages of eighteen and thirty-five and has seen the strongest increase in incidence among all cancer types over the last 20 years. Despite this, the cure rate, which was very low in the 1970's and 1980's, improved dramatically following the introduction of platinum-based chemotherapy.
This high cure rate changed the treatment strategy in virtually all stages of testicular cancer, away from aggressive surgical or radiation treatment to that of surveillance without treatment or minimal treatment for most patients in early stages and only limited chemotherapy in advanced stages.
However, it remains that a minority of patients with germ cell cancer still die from their disease.

All these changes in treatment approach, encompassing several options for patients, need highly informed and experienced doctors, both to give the patient the best advice on selecting optimal treatment and then to implement with expertise the adopted course. The ESMO Symposium on Testicular Cancer will present the most recent information about biology and molecular background in order to understand the high chemo-sensitivity of this tumor, prognostic factors and decision-making options for individual patients. In particular, treatment options will be discussed against the background of the European Consensus Guidelines.

The ESMO Symposium on Testicular Cancer will give a complete overview of current
knowledge in tumor biology and in particular treatment of germ cell cancer in men, including practical advice for the clinical routine.

ESMO Symposium on Testicular Cancer officers

ESMO Symposia Working Group

Mario Dicato, Luxembourg, Chair
Jørn Herrstedt, Denmark
Dirk Schrijvers, Belgium